Shots:

• The NICE has issued FAD which is based on the P-III ICARIA-MM trial assessing isatuximab + pom-dex vs pom-dex in patients prior treated with 3L treatment and at least 2L therapies including lenalidomide and a proteasome inhibitor with RRMM in 307 patients with RRMM
• The study demonstrated that the combination regimen demonstrated a reduction in risk of disease progression or death in adults by 40%- mPFS (11.5 vs 6.5)- well-tolerated with no increase in treatment discontinuation
• Isatuximab is a mAb that binds to a specific site on CD38 and is now available to eligible patients through the NHS Cancer Drugs Fund. Isatuximab is the first mAb approved in EU to be used in combination with pom-dex for RRMM

 ­ Ref: Sanofi | Image: Bloomberg